Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz

February 9, 2024
Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared HolzAmgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz
Share This

Jared Holz, Mizuho, joins ‘Closing Bell Overtime’ to talk Amgen’s obesity drug trial results.


 

Latest Mizuho News

Mizuho’s Jared Holz on Moderna’s leg up on new cancer shot data

Mizuho’s Jared Holz on Moderna’s leg up on new cancer shot data

August 19, 2026
Nvidia holders to focus on AI data, Mizuho's Rakesh says

Nvidia holders to focus on AI data, Mizuho's Rakesh says

August 26, 2026
Mizuho Retains “Outstanding” Community Reinvestment Act Ratings

Mizuho Retains “Outstanding” Community Reinvestment Act Ratings

August 10, 2026

Mizuho news from around the globe

back-to-top-blue